F

Faculdade de Medicina de Botucatu | Unesp

Research site

(Unclaimed)

Location

Avenida Prof. Armando Alves s/nº - UNESP - Campus de Botucatu, Botucatu, Sao Paulo, Brazil

Site insights

Top conditions

Top treatments

Baricitinib

Azithromycin

Apixaban

Mirikizumab

JNJ-53718678

Hydroxychloroquine

Remifentanil

Vedolizumab

REGN7508

S42909

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 13 total trials

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with sy...

Active, not recruiting

Systemic Juvenile Idiopathic Arthritis

Drug: Baricitinib

Drug: Tocilizumab

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This st...

Enrolling

Juvenile Idiopathic Arthritis

Drug: Baricitinib

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease (VICTRIVA)

The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel i...

Enrolling

Crohn's Disease

Drug: Vedolizumab

Drug: Placebo

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation (ROXI-ATLAS)

This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which m...

Enrolling

Atrial Fibrillation (AF)

Drug: REGN9933

Drug: REGN7508